Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/2162402X.2015.1008814 http://scihub22266oqcxt.onion/10.1080/2162402X.2015.1008814 C4485728!4485728!26137403     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26137403.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Oncoimmunology 2015 ; 4 (4): ä Nephropedia Template TP {{tp|p=26137403|t=2015. Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications |pdf=|usr=}}{{26137403}} gab.com Text Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications JO: Oncoimmunology http://www.kidney.de/pget.php?&tw=1&pmid=26137403 #FOAvip Immunomodulatory monoclonal antibodies (mAbs) differ from their tumor-targeting counterparts because they exert therapeutic effects by directly interacting with soluble or (most often) cellular components of the immune system. Besides holding promise for the treatment of autoimmune and inflammatory disorders, immunomodulatory mAbs have recently been shown to constitute a potent therapeutic weapon against neoplastic conditions. One class of immunomodulatory mAbs operates by inhibiting safeguard systems that are frequently harnessed by cancer cells to establish immunological tolerance, the so-called ?immune checkpoints.? No less than 3 checkpoint-blocking mAbs have been approved worldwide for use in oncological indications, 2 of which during the past 12 months. These molecules not only mediate single-agent clinical activity in patients affected by specific neoplasms, but also significantly boost the efficacy of several anticancer chemo-, radio- or immunotherapies. Here, we summarize recent advances in the development of checkpoint-blocking mAbs, as well as of immunomodulatory mAbs with distinct mechanisms of action. Twit Text FOAVip Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications ????Oncoimmunology http://www.kidney.de/pget.php?&tw=1&pmid=26137403 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26137403 #FOAvip English Wikipedia <ref>{{Cite pmid|26137403}}</ref> Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications #MMPMID26137403 Buqué A; Bloy N; Aranda F; Castoldi F; Eggermont A; Cremer I; Fridman WH; Fucikova J; Galon J; Marabelle A; Spisek R; Tartour E; Zitvogel L; Kroemer G; Galluzzi L Oncoimmunology 2015[Apr]; 4 (4): ä PMID26137403show ga Immunomodulatory monoclonal antibodies (mAbs) differ from their tumor-targeting counterparts because they exert therapeutic effects by directly interacting with soluble or (most often) cellular components of the immune system. Besides holding promise for the treatment of autoimmune and inflammatory disorders, immunomodulatory mAbs have recently been shown to constitute a potent therapeutic weapon against neoplastic conditions. One class of immunomodulatory mAbs operates by inhibiting safeguard systems that are frequently harnessed by cancer cells to establish immunological tolerance, the so-called ?immune checkpoints.? No less than 3 checkpoint-blocking mAbs have been approved worldwide for use in oncological indications, 2 of which during the past 12 months. These molecules not only mediate single-agent clinical activity in patients affected by specific neoplasms, but also significantly boost the efficacy of several anticancer chemo-, radio- or immunotherapies. Here, we summarize recent advances in the development of checkpoint-blocking mAbs, as well as of immunomodulatory mAbs with distinct mechanisms of action. äTrial Watch: Immunomodulatory monoclonal antibodies for oncological in(epmc).pdf DeepDyve Pubget Overpricing